• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Avista Capital Managing Member V, Llc converted options into 17,770 shares (SEC Form 4)

    11/14/23 9:47:11 PM ET
    $AHPA
    Get the next $AHPA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Avista Capital Managing Member V, LLC

    (Last) (First) (Middle)
    65 EAST 55TH STREET
    18TH FLOOR

    (Street)
    NEW YORK NY 10022

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    OmniAb, Inc. [ OABI ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    11/01/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common stock, par value $0.0001 per share 11/01/2023 M(3) 17,770 A (4) 15,835,704(7)(8)(9) I See Notes(1)(2)(11)(13)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Restricted Stock Units (4) 11/01/2023 M(3) 17,770 (4)(10) (4)(10) Common stock, par value $0.0001 17,770 (4) 35,538(4)(10) I See Notes(1)(2)(11)
    Restricted Stock Units (5) (5) (5) Common stock, par value $0.0001 20,000 20,000 I See Notes(1)(2)(11)
    Stock Options $4.81 (6) 06/23/2033 Common stock, par value $0.0001 40,000(6) 40,000(6) I See Notes(1)(6)(11)
    Stock Options $3.35 (14) 12/01/2032 Common stock, par value $0.0001 200,000(14) 200,000(14) I See Notes(1)(11)(14)
    Warrants $11.5 (12)(13) 11/01/2027 Common stock, par value $0.0001 11,345,489 11,345,489 I See Notes(1)(2)(13)
    1. Name and Address of Reporting Person*
    Avista Capital Managing Member V, LLC

    (Last) (First) (Middle)
    65 EAST 55TH STREET
    18TH FLOOR

    (Street)
    NEW YORK NY 10022

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Avista Capital Partners V GP, L.P.

    (Last) (First) (Middle)
    65 EAST 55TH STREET
    18TH FLOOR

    (Street)
    NEW YORK NY 10022

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Avista Capital Partners V, L.P.

    (Last) (First) (Middle)
    65 EAST 55TH STREET
    18TH FLOOR

    (Street)
    NEW YORK NY 10022

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Avista Capital Partners (Offshore) V, L.P.

    (Last) (First) (Middle)
    65 EAST 55TH STREET
    18TH FLOOR

    (Street)
    NEW YORK NY 10022

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Burgstahler David F

    (Last) (First) (Middle)
    65 EAST 55TH STREET
    18TH FLOOR

    (Street)
    NEW YORK NY 10022

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Dean Thompson

    (Last) (First) (Middle)
    65 EAST 55TH STREET
    18TH FLOOR

    (Street)
    NEW YORK NY 10022

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Tamaroff Joshua Alexander

    (Last) (First) (Middle)
    65 EAST 55TH STREET
    18TH FLOOR

    (Street)
    NEW YORK NY 10022

    (City) (State) (Zip)
    Explanation of Responses:
    1. This form is being filed by each of the following Reporting Persons: (i) Avista Capital Partners V, L.P., a Delaware limited partnership ("ACP V Onshore"), (ii) Avista Capital Partners (Offshore) V, L.P., a Bermuda limited partnership ("ACP V Offshore"), (iii) Avista Capital Partners V GP, L.P., a Delaware limited partnership ("ACP V GP"), which is the general partner of ACP V Onshore and ACP V Offshore, (iv) Avista Capital Managing Member V, LLC, a Delaware limited liability company ("Avista Managing Member"), which is the general partner of ACP V GP, (v) each of Thompson Dean and David Burgstahler, who are the managers of Avista Managing Member (together with ACP V GP and Avista Managing Member, the "Avista Affiliates"), and (vi) Joshua Tamaroff, who is a director of OmniAb, Inc. (f/k/a Avista Public Acquisition Corp. II) (the "Issuer").
    2. ACP V Onshore directly holds 7,283,484 shares of common stock and 5,224,114 warrants. ACP V Offshore directly holds 8,534,450 shares of common stock and 6,121,375 warrants. Each of the Avista Affiliates may be deemed to beneficially own the securities reported on this line item to the extent of their respective pecuniary interests. Each of the Avista Affiliates disclaims beneficial ownership of the securities reported on this line item, except to the extent of their pecuniary interest therein, if any.
    3. Vesting of restricted stock units ("RSUs") previously granted to the Reporting Persons.
    4. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Vesting occurs in three substantially equal annual installments, beginning November 1, 2023.
    5. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in full on the earlier of (i) the date of the next annual meeting of the Company's stockholders following the grant date and (ii) the first anniversary of the grant date.
    6. Represents stock options granted to Mr. Tamaroff in his capacity as a director of the Issuer, which stock options vest and become exercisable in full on the earlier of (i) the date of the next annual meeting of the Company's stockholders following the grant date and (ii) the first anniversary of the grant date.
    7. In accordance with the letter agreement, dated March 23, 2022, by and among the Issuer, Avista Acquisition LP II, a Cayman Islands limited partnership ("Avista Sponsor"), and other parties (the "Letter Agreement"), if the Triggering Event (as defined in the Letter Agreement) has not occurred during the Earnout Period (as defined in the Letter Agreement), 1,293,299 shares of common stock will be automatically forfeited to the Issuer for no consideration.
    8. As a result of the liquidation and distribution of all of the assets of the Avista Sponsor to its limited partners, ACP V Onshore and ACP V Offshore (the "Avista Sponsor Liquidating Distribution"), and pursuant to a Joinder to the Letter Agreement entered into on December 9, 2022 between ACP V Onshore, ACP V Offshore, Avista Sponsor and the Issuer, ACP V Onshore directly holds 595,508 of the shares of common stock subject to forfeiture pursuant to the terms of the Letter Agreement, and ACP V Offshore holds 697,791 of the shares of common stock subject to forfeiture pursuant to the terms of the Letter Agreement.
    9. Additionally, in connection with the Avista Sponsor Liquidating Distribution, each of ACP V Onshore and ACP V Offshore provided to the Issuer an agreement stating that they will each be bound by the transfer restrictions included in the Amended and Restated Registration and Stockholder Rights Agreement, dated as of November 1, 2022, among the Issuer, the Sponsor and the other signatories thereto (the "A&R RSRA") for the duration of the Founder Shares Lock Up Period (as defined in the A&R RSRA).
    10. Represents restricted stock units ("RSUs") granted to Mr. Tamaroff in his capacity as a director of the Issuer, which RSUs vest as to the shares underlying the award in three substantially similar annual installments beginning on November 1, 2023, subject to Mr. Tamaroff's continuing service as a director of the Issuer through the applicable vesting date; provided, that the RSUs shall vest in full (i) in the event of a Change of Control (as defined in the Issuer's 2022 Incentive Award Plan), to the extent Mr. Tamaroff is serving as a director at the time of such transaction, or (ii) in the event that Mr. Tamaroff ceases to serve as a director by reason of death or Permanent Disability (as defined in the Issuer's 2022 Incentive Award Plan).
    11. Mr. Tamaroff is a partner at an affiliate of the Avista Affiliates and has assigned all rights, title and interest in any securities of the Issuer to an affiliate of the Avista Affiliates controlled by Mr. Dean and Mr. Burgstahler. The Avista Affiliates, ACP V Onshore and ACP V Offshore are each "directors by deputization" for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended. Each of the Avista Affiliates and Mr. Tamaroff may be deemed to beneficially own the securities reported on this line item to the extent of their respective pecuniary interests. Each of the Avista Affiliates, ACP V Onshore and ACP V Offshore and Mr. Tamaroff disclaims beneficial ownership of the securities issued to Mr. Tamaroff, except to the extent of their pecuniary interest therein, if any.
    12. In connection with the completion of the Issuer's August 2021 initial public offering, Avista Sponsor purchased 8,233,333 warrants in a private placement from the Issuer, each exercisable to purchase (subject, initially, to the satisfaction of certain material conditions) one share of common stock for $11.50 per share. The material conditions to exercise were satisfied upon the closing of the transactions contemplated by the Agreement and Plan of Merger, dated March 23, 2022, by and among the Issuer, Avista Sponsor and other parties (the "Closing"), and the warrants by their terms became exercisable (including by cash settlement) on December 1, 2022.
    13. In connection with the Amended and Restated Forward Purchase Agreement, dated March 23, 2022, by and among the Issuer, Avista Sponsor and other parties (the "A&R Forward Purchase Agreement"), Avista Sponsor purchased an aggregate 3,112,156 warrants in private placements from the Issuer, each exercisable to purchase (subject, initially, to the satisfaction of certain material conditions) one share of common stock for $11.50 per share. The material conditions to exercise were satisfied on the Closing, and the warrants by their terms became exercisable (including by cash settlement) December 31, 2022.
    14. Represents stock options granted to Mr. Tamaroff in his capacity as a director of the Issuer, which stock options vest in three substantially similar annual installments beginning on November 1, 2023. The Form 4s filed by the Reporting Persons on December 5, 2022 and December 13, 2022 incorrectly reported that 161,849 stock options and 161,849 shares of common stock underlying such stock options were issued to Mr. Tamaroff.
    Remarks:
    Exhibit 99.1 (Joint Filer Information and Signatures) is hereby incorporated by reference herein.
    See Exhibit 99.1 11/14/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $AHPA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AHPA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AHPA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Higgins John L converted options into 13,173 shares, increasing direct ownership by 0.56% to 2,352,625 units (SEC Form 4)

      4 - OmniAb, Inc. (0001846253) (Issuer)

      1/31/24 7:58:15 PM ET
      $AHPA
    • Foehr Matthew W converted options into 33,173 shares and covered exercise/tax liability with 13,221 shares, increasing direct ownership by 0.75% to 2,665,394 units (SEC Form 4)

      4 - OmniAb, Inc. (0001846253) (Issuer)

      1/3/24 5:42:40 PM ET
      $AHPA
    • Berkman Charles S converted options into 17,556 shares and covered exercise/tax liability with 7,195 shares, increasing direct ownership by 4% to 272,317 units (SEC Form 4)

      4 - OmniAb, Inc. (0001846253) (Issuer)

      1/3/24 5:42:11 PM ET
      $AHPA

    $AHPA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Foehr Matthew W bought $1,010,000 worth of shares (200,000 units at $5.05), increasing direct ownership by 8% to 2,645,442 units (SEC Form 4)

      4 - OmniAb, Inc. (0001846253) (Issuer)

      12/13/23 3:25:06 PM ET
      $AHPA
    • Foehr Matthew W bought $405,517 worth of shares (95,000 units at $4.27), increasing direct ownership by 4% to 2,427,919 units (SEC Form 4)

      4 - OmniAb, Inc. (0001846253) (Issuer)

      11/13/23 8:00:05 AM ET
      $AHPA

    $AHPA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • OmniAb Reports Third Quarter 2022 Financial Results and Business Highlights

      OmniAb, Inc. (NASDAQ:OABI) reported financial results for the three and nine months ended September 30, 2022 and provided operating and program updates. OmniAb was part of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) until its spin-off as an independent publicly traded company as of November 1, 2022. As such, OmniAb will not file a Form 10-Q with the U.S. Securities and Exchange Commission (SEC) for the three months ended September 30, 2022; however, its third quarter financial results have been reported on a Form 8K/A that can be found here. Avista Public Acquisition Corp. II (which changed its name to OmniAb, Inc. in connection with the merger) filed a Form 10-Q under the name of Omn

      11/15/22 7:00:00 AM ET
      $AHPA
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OmniAb Announces Completion of Spin-Off and Business Combination

      Leading Antibody Discovery Technologies Enable Development of Innovative Therapeutics Regular-way Trading of OABI Begins November 2, 2022 on Nasdaq OmniAb, Inc. (NASDAQ:OABI) today announced the completion of the expected tax-free spin-off from Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and the subsequent business combination with Avista Public Acquisition Corp. II (NASDAQ:AHPA), resulting in OmniAb becoming an independent publicly traded company. Based on actual redemptions and estimated transaction expenses, OmniAb expects to have approximately $95 million in cash at closing. OmniAb will begin regular-way trading November 2, 2022 on Nasdaq under the stock ticker symbol "OABI." "

      11/1/22 4:01:00 PM ET
      $AHPA
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ligand Announces that Janssen has Received Approval from U.S. FDA for TECVAYLI™ (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

      First FDA approval of a bispecific antibody discovered using OmniAb technology OmniAb, Inc. is eligible to receive a $25 million milestone upon first commercial sale in the United States Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced that Janssen Biotech, Inc. (Janssen) has received approval from the U.S. Food and Drug Administration (FDA) for TECVAYLI™ (teclistamab) for the treatment of patients with relapsed or refractory (R/R) multiple myeloma. Teclistamab is a T-cell redirecting, bispecific antibody targeting both B-cell maturation antigen (BCMA) and CD3 discovered and developed by Janssen scientists using OmniAb's OmniRat® antibody discovery technology. Under the terms

      10/26/22 8:00:00 AM ET
      $AHPA
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AHPA
    SEC Filings

    See more
    • SEC Form EFFECT filed by Avista Public Acquisition Corp. II

      EFFECT - OmniAb, Inc. (0001846253) (Filer)

      12/19/23 12:15:27 AM ET
      $AHPA
    • SEC Form EFFECT filed by Avista Public Acquisition Corp. II

      EFFECT - OmniAb, Inc. (0001846253) (Filer)

      12/19/23 12:15:16 AM ET
      $AHPA
    • SEC Form POS AM filed by Avista Public Acquisition Corp. II

      POS AM - OmniAb, Inc. (0001846253) (Filer)

      12/8/23 5:09:26 PM ET
      $AHPA

    $AHPA
    Leadership Updates

    Live Leadership Updates

    See more
    • OmniAb Announces Completion of Spin-Off and Business Combination

      Leading Antibody Discovery Technologies Enable Development of Innovative Therapeutics Regular-way Trading of OABI Begins November 2, 2022 on Nasdaq OmniAb, Inc. (NASDAQ:OABI) today announced the completion of the expected tax-free spin-off from Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and the subsequent business combination with Avista Public Acquisition Corp. II (NASDAQ:AHPA), resulting in OmniAb becoming an independent publicly traded company. Based on actual redemptions and estimated transaction expenses, OmniAb expects to have approximately $95 million in cash at closing. OmniAb will begin regular-way trading November 2, 2022 on Nasdaq under the stock ticker symbol "OABI." "

      11/1/22 4:01:00 PM ET
      $AHPA
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AHPA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Avista Public Acquisition Corp. II (Amendment)

      SC 13G/A - OmniAb, Inc. (0001846253) (Subject)

      2/13/24 5:57:04 PM ET
      $AHPA
    • SEC Form SC 13G filed by Avista Public Acquisition Corp. II

      SC 13G - OmniAb, Inc. (0001846253) (Subject)

      1/29/24 3:26:24 PM ET
      $AHPA
    • SEC Form SC 13G/A filed by Avista Public Acquisition Corp. II (Amendment)

      SC 13G/A - OmniAb, Inc. (0001846253) (Subject)

      3/8/23 2:15:29 PM ET
      $AHPA

    $AHPA
    Financials

    Live finance-specific insights

    See more
    • Ligand Reports Second Quarter 2022 Financial Results

      Raises 2022 Financial Guidance Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2022 and provided an operating forecast and program updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. "2022 continues to be an outstanding year for Ligand, in particular as royalties from our Pelican Expression Technology platform grow into meaningful revenue contributors," said John Higgins, CEO of Ligand. "The business is enjoying good momentum with numerous positive late-stage de

      8/8/22 4:01:00 PM ET
      $AHPA
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ligand Reports First Quarter 2022 Financial Results

      Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2022 and provided an operating forecast and program updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. "2022 is off to a strong start with solid financial performance from our growing roster of royalty-bearing products and great execution from all our core technology platforms," said John Higgins, CEO of Ligand. "We are excited about the potential growth of our business in the years to come as several recently approved pr

      5/4/22 4:01:00 PM ET
      $AHPA
      $LGND
      Biotechnology: Pharmaceutical Preparations
      Health Care